Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites

Journal of Medicinal Chemistry

Volumn 46, Issue 12, 2003, Pages 2261-2270

  Schmidt, Boris ^a,b   Schieffer, Bernhard ^a,b  

^a DARMSTADT UNIVERSITY OF TECHNOLOGY   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CANDESARTAN HEXETIL; DRUG METABOLITE; EPROSARTAN; IRBESARTAN; LOSARTAN; TASOSARTAN; TELMISARTAN; VALSARTAN;

DRUG ABSORPTION; DRUG MECHANISM; DRUG METABOLISM; DRUG OXIDATION; DRUG RECEPTOR BINDING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ACRYLATES; ANGIOTENSIN II; ANIMALS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; GROWTH HORMONE; HUMANS; HYPERTENSION; IMIDAZOLES; LOSARTAN; MODELS, MOLECULAR; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, ANGIOTENSIN; TETRAZOLES; THIOPHENES; THROMBOXANE A2;

EID: 0038101440     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0204237     Document Type: Review

References (103)

1. Puri, P. L.; Avantaggiati, L.; Burgio, V. L.; Chirillot, P.; Collepardo, D.; et al. Reactive oxygen intermediates mediate angiotensin II induced c-JUNC FOS heterodimer DNA binding activity and proliferative hypertrophic responses in myogenic cells. J. Biol. Chem. 1995, 270, 22129-22134.
2. Benigni, A.; Perico, N.; Remuzzi, G. Endothelin antagonists and renal protection. J. Cardiovasc. Pharmacol. 2000, 35, S75-S78.
3. Wolny, A.; Clozel, J. P.; Rein, J.; Mory, P.; Vogt, P.; et al. Functional and biochemical analysis of angiotensin II-forming pathways in the human heart. Circ. Res. 1997, 80, 219-227.
4. Levine, B.; Kalman, J.; Mayer, L.; Fillit, H. M.; Packer, M. Elevated circulating tumor necrosis factor in patients with severe chronic heart failure. N. Engl. J. Med. 1990, 323, 236-241.
5. Griendling, K. K.; Minieri, C. A.; Ollerenshaw, J. D.; Alexander, R. W. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured smooth muscle cells. Circ. Res. 1994, 74, 1141-1148.
6. Mayer, A. M. S.; Brenic, S.; Glaser, K. B. Pharmacological targeting of signaling pathways in protein kinase C-stimulated superoxide generation in neutrophil-like HL-60 cells: effect of phorbol ester, arachidonic acid and inhibitors of kinase(s), phosphatase(s) and phospholipase A2. J. Pharmacol. Exp. Ther. 1996, 279, 633-644.
7. Beckman, J. S.; Beckman, T. W.; Chen, J.; Marshall, P. A.; Freeman, B. A. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc. Natl. Acad. Sci. U.S.A. 1990, 87, 1620-1624.
8. Wong, P. C.; Price, W. A.; Chiu, A. T.; Duncia, J. V.; Carini, D. J.; et al. Non-peptide angiotensin II receptor antagonists. IX. Antihypertensive activity in rats of DuP753, an orally active antihypertensive agent. J. Pharmacol. Exp. Ther. 1990, 252, 719.
9. Raij, L.; Baylis, C. Glomerular actions of nitric oxide. Kidney Int. 1995, 48, 20-32.
10. Pollman, M. J.; Yamada, T.; Horiuchi, M.; Gibbons, G. H. Vasoactive substances regulate vascular smooth muscle cell apoptosis. Countervailing influences of nitric oxide and angiotensin II. Circ. Res. 1996, 79, 748-756.
11. Kagami, S.; Border, W.; Miller, D. E.; Noble, N. A. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-b expression in rat glomerular mesangial cells. J. Clin. Invest. 1994, 93, 2431-2437.
12. Wilkes, B. C.; Masaro, L.; Schiller, P. W.; Carpenter, K. A. Angiotensin II vs Its Type I Antagonists: Conformational Requirements for Receptor Binding Assessed from NMR Spectroscopic and Receptor Docking Experiments. J. Med. Chem. 2002, 45, 4410-4418.
13. Schmidt, B.; Lindman, S.; Tong, W.; Lindeberg, G.; Gogoll, A.; et al. Design, Synthesis, and Biological Activities of Four Angiotensin II Receptor Ligands with g-Turn Mimetics Replacing Amino Acid Residues 3-5. J. Med. Chem. 1997, 40, 903-919.
14. Spear, K. L.; Brown, M. S.; Reinhard, E. J.; McMahon, E. G.; Olins, G. M.; et al. Conformational restriction of angiotensin II: cyclic analogs having high potency. J. Med. Chem. 1990, 33, 1935-1940.
15. Duncia, J. V.; Carini, D. J.; Chiu, A. T.; Johnson, A. L.; Price, W. A.; et al. The Discovery of DUP-753, a Potent, Orally Active Nonpeptide Angiotensin II Receptor Antagonist. Med. Res. Rev. 1992, 12, 149-191.
16. Duncia, J. V.; Chiu, A. T.; Carini, D. J.; Gregory, G. B.; Johnson, A. L.; et al. The Discovery of Potent Nonpeptide Angiotensin II Receptor Antagonists: A New Class of Potent Antihypertensives. J. Med. Chem. 1990, 33, 1312-1329.
17. Israili, Z. H. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J. Hum. Hypertens. 2000, 14 (Suppl. 1), S73-S86.
18. Wong, P. C.; Price, W. A.; Chiu, A. T.; Duncia, J. V.; Carini, D.; et al. Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP 3174: An active metabolite of DuP 753, an orally active antihypertensive agent. J. Pharmacol. Exp. Ther. 1990, 255, 211-217.
19. Wexler, R. R.; Greenlee, W. J.; Irvin, J. D.; Goldberg, M. R.; Prendergast, K.; et al. Nonpeptide Angiotensin II Receptor Antagonists: The Next Generation in Antihypertensive Therapy. J. Med. Chem. 1996, 39, 625-656.
20. Ohyama, K.; Yamano, Y.; Chaki, S.; Kondo, T.; Inagami, T. Domains for G-protein coupling in angiotensin II receptor type I: studies by site-directed mutagenesis. Biochem. Biophys. Res. Commun. 1992, 189, 677-683.
21. Prendergast, K.; Adams, K.; Greenlee, W. J.; Nachbar, R. B.; Patchett, A. A.; et al. Derivation of a 3D pharmacophore model for the angiotensin-II site one receptor. J. Comput.-Aided Mol. Des. 1994, 8, 491-512.
22. Noda, K.; Saad, Y.; Kinoshita, A.; Boyle, T. P.; Graham, R. M.; et al. Tetrazole and carboxylate groups of angiotensin receptor antagonists bind to the same subsite by different mechanisms. J. Biol. Chem. 1995, 270, 2284-2289.
23. Schambye, H. T.; Hjorth, S. A.; Weinstock, J.; Schwartz, T. W. Interaction between the nonpeptide angiotensin antagonist SKF108,566 and histidine 256 (HisVI: 16) of the angiotensin type 1 receptor. Mol. Pharmacol. 1995, 47, 425-431.
24. Lo, M.-W.; Goldberg, M. R.; McRea, J. B.; Lu, H.; Furtek, C. I.; et al. Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP 3174 in humans. Clin. Pharmacol. Ther. 1995, 58, 641-649.
25. Farthing, D.; Sica, D.; Fakhry, I.; Pedro, A.; Gehr, T. W. B. Simple high-performance liquid chromatographic method for determination of losartan and E-3174 metabolite in human plasma, urine and dialysate. J. Chromatogr., B 1997, 704, 374-378.
26. Yun, C.-H.; Lee, H. S.; Rho, H. K.; Jeong, H. G.; Guengerich, F. P. Oxidation of the angiotensin II receptor antagonist Losartan (DuP 753) in human liver microsomes. Drug Metab. Dispos. 1995, 23, 285-289.
27. Stearns, R. A.; Miller, R. R.; Doss, G. A.; Chakravarty, P. K.; Rosegay, A.; et al. The metabolism of DuP 753, a nonpeptide angiotensin II receptor antagonist, by rat, monkey, and human liver slices. Drug Metab. Dispos. 1992, 20, 281-287.
28. Stearns, R. A.; Chakravarty, P. C.; Chen, R.; Chiu, S.-H. L. Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Drug Metab. Dispos. 1995, 23, 207-215.
29. Csajka, C.; Buclin, T.; Brunner, H. R.; Biollaz, J. Pharmocokinetic-Pharmacodynamic Profile of Angiotensin II Receptor Antagonists. Clin. Pharmacokinet. 1997, 32, 1-29.
30. Chiu, S.-H. L. The Use of In Vitro Metabolism Studies in the Understanding of New Drugs. J. Pharmacol. Toxicol. Methods 1993, 29, 77-83.
31. Sweet, C. S.; Bradstreet, D. C.; Berman, R. S.; Jallard, N.; Saenz, A.; et al. Pharmocodynamic activity of intravenous E-3174, an angiotensin II antagonist, in patients with essential hypertension. Am. J. Hypertens. 1994, 7, 1035-1040.
32. Christ, D. D. Human Plasma Protein Binding of the Angiotensin II Receptor Antagonist Losartan Potassium (DuP 753/MK 954) and Its Pharmacologically Active Metabolite EXP3174. J. Clin. Pharmacol. 1995, 35, 515-520.
33. 1-selective non-peptide angiotensin II receptor antagonist. Eur. J. Clin. Pharmacol. 1995, 49, 115-119.
34. Soldner, A.; Benet, L. Z.; Mutschler, E.; Christians, U. Active transport of the angiotensin-II antagonist losartan and its main metabolite EXP 3174 across MDCK-MDR1 and Caco-2 cell monolayers. Br. J. Pharmacol. 2000, 129, 1235-1243.
35. Chen, T. S.; So, L.; White, R.; Monaghan, L. Microbial Hydroxylation and Glucoronidation of the Angiotensin II(AII) Receptor Antagonist MK 954. J. Antibiot. 1993, 46, 131-134.
36. Krieter, P. A.; Colletti, A. E.; Miller, R. R.; Stearns, R. A. Absorption and Glucoronidation of the Angiotensin II Receptor Antagonist Losartan by the Rat Intestine. J. Pharmacol. Exp. Ther. 1995, 273, 816-822.
37. Bauer, M.; Harris, R. K.; Rao, R. C.; Apperley, D. C.; Rodger, C. A. NMR study of desmotropy in irbesartan, a tetrazole-containing pharmaceutical compound. J. Chem. Soc., Perkin Trans. 2 1998, 475-481.
38. Stearns, R. A.; Doss, G. A.; Miller, R. R.; Chiu, S.-H. L. Synthesis and Identification of a Novel Tetrazole Metabolite of the Angiotensin II Receptor Antagonist DuP 753. Drug Metab. Dispos. 1991, 19, 207-215.
39. Huskey, S.-E. W.; Miller, R. R.; Chiu, S.-H. L. N-Glucoronidation Reaction. I. Tetrazole N-Glucoronidation of Selected Angiotensin II Receptor Antagonists in Hepatic Microsomes from Rats, Dogs, Monkeys, and Humans. Drug Metab. Dispos. 1993, 21, 792-799.
40. Kaukonen, K.-M.; Olkkola, K. T.; Neuvonen, P. J. Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174. Eur. J. Clin. Pharmacol. 1998, 53, 445-449.
41. Kazierad, D. J.; Martin, D. E.; Blum, R. A.; Tenero, D. M.; Ilson, B.; et al. Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers. Clin. Pharmacol. Ther. 1997, 62, 417-425.
42. Goldberg, M. R.; Lo, M. W.; Deutsch, P. J.; Wilson, S. E.; McWilliams, E. J.; et al. Phenobarbital minimally alters plasma concentrations of losartan and its active metabolite E-3174. Clin. Pharm. Ther. 1996, 59, 268-274.
43. Yasar, U.; Tybring, G.; Hidestrand, M.; Oscarson, M.; Ingelman-Sundberg, M.; et al. Role of CYP2C9 polymorphism in losartan oxidation. Drug Metab. Dispos. 2001, 29, 1051-1056.
44. Zaidenstein, R.; Soback, S.; Gips, M.; Avni, B.; Dishi, V.; et al. Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers. Ther. Drug Monit. 2001, 23, 369-373.
45. Taavitsainen, P.; Kiukaanniemi, K.; Pelkonen, O. In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists. Eur. J. Clin. Pharmacol. 2000, 56, 135-140.
46. 1-receptor antagonists. Correlation with complementary LC data reveals a potential contribution of active metabolites. J. Pharm. Biomed. Anal. 1998, 17, 111-124.
47. Ohta, H.; Satomi, T.; Suzuki, J.; Ikemoto, F.; Nishikibe, M. Pharmacological characteristics and clinical application of losartan, an orally active AT1 angiotensin II receptor antagonist. Nippon Yakurigaku Zasshi. 1999, 113, 331-338.
48. Furuse, M.; Hamada, T.; Sonoyama, K.; Yamamoto, Y.; Ozaki, S.; et al. Mechanism of angiotensin II receptor antagonist losartan on uric acid metabolism. Tsufu to Kakusan Taisha 2000, 24, 31-37.
49. 1 receptor antagonists - Are there differences? Herz 1997, 22, 357-360.
50. Li, P.; Ferrario, C. M.; Broshnihan, K. B. Nonpeptide Angiotensin II Antagonist Losartan Inhibits Thromboxane A2-Induced Contractions in Canine Coronary Arteries. J. Pharmacol. Exp. Ther. 1997, 281, 1065-1070.
51. Caballero, R.; Delpon, E.; Valenzuela, C.; Longobardo, M.; Tamargo, J. Losartan and its metabolite E3174 modify cardiac delayed rectifier K+ currents. Circulation 2000, 101, 1199-1205.
52. Soldner, A.; Spahn-Langguth, H.; Mutschler, E. HPLC assays to simultaneously determine the angiotensin-AT1 antagonist losartan as well as its main and active metabolite, EXP 3174, in biological material of humans and rats. J. Pharm. Biomed. Anal. 1998, 16, 863-873.
53. Tenero, D.; Martin, D.; Chapelsky, M.; Ilson, B.; Boike, S.; et al. Effect of Hepatic Disease on the Pharmacokinetics and Plasma Protein Binding of Eprosartan. Pharmacotherapy 1998, 18, 42-50.
54. Cox, P.; Bush, B.; Gorycki, P. The Metabolic Fate of Eprosartan in Healthy Volunteers. Exp. Toxicol. Pathol. 1996, 48, 5.
55. McClellan, K. J.; Balfour, J. A. Eprosartan. Drugs 1998, 55, 713-720.
56. Hedner, T. The clinical profile of the angiotensin II receptor blocker eprosartan. J. Hypertens. 2002, 20, S33-S38.
57. Puig, J. G.; Mateos, F.; Buno, A.; Ortega, R.; Rodriguez, F.; et al. Effect of eprosartan and losartan on uric acid metabolism in patients with essential hypertension. J. Hypertens. 1999, 17, 1033-1039.
58. Sica, D. A.; Marino, M. R.; Hammett, J. L.; Ferreira, I.; Gehr, T. W. B.; et al. The pharmacokinetics of irbesartan in renal failure and maintenance hemodialysis. Clin. Pharmacol. Ther. 1997, 62, 610-618.
59. Chando, T. J.; Everett, D. W.; Kahle, A. D.; Starret, A. M.; Vachharajani, N.; et al. Biotransformation of Irbesartan in Man. Drug Metab. Dispos. 1998, 26, 408-417.
60. 1-receptor antagonist, in mice, rats, rabbits, and macaques. Drug Metab. Dispos. 2000, 28, 79-88.
61. Bourrie, M.; Meunier, V.; Berger, Y.; Fabre, G. Role of cytochrome P-4502C9 in irbesartan oxidation by human liver microsomes. Drug Metab. Dispos. 1999, 27, 288-296.
62. Waldmeier, F.; Flesch, G.; Müller, P.; Winkler, T.; Kriemler, H.P.; et al. Pharmocokinetics, disposition and biotransformation of [14C]-radiolabelled valsartan in healthy male volunteers after a single dose. Xenobiotica 1997, 27, 59-71.
63. Ellingboe, J. W.; Collini, M. D.; Quagliato, D.; Chen, J.; Antane, M.; et al. Metabolites of the Angiotensin II Antagonist Tasosartan: The Importance of a Second Acidic Group. J. Med. Chem., 1998, 41, 4251-4260.
64. Lacourciere, Y.; Pool, J. L.; Svetkey, L.; Gradman, A. H.; Larochelle, P.; et al. A randomized, double-blind, placebo-controlled, parallel-group, multicenter trial of four doses of tasosartan in patients with essential hypertension. Tasosartan Investigator's Group. Am. J. Hypertens. 1998, 11, 454-461.
65. Elokdah, H. M.; Friedrichs, G. S.; Chai, S.-Y.; Harrison, B. L.; Primeau, J.; et al. Novel human metabolites of the angiotensin-II antagonist tasosartan and their pharmacological effects. Bioorg. Med. Chem. Lett. 2002, 12, 1967-1971.
66. Gleiter, C. H.; Morike, K. E. Clinical pharmacokinetics of candesartan. Clin. Pharmacokinet. 2002, 41, 7-17.
67. Miyabayashi, T.; Okuda, T.; Motohashi, M.; Izawa, K.; Yashiki, T. Quantitation of a new potent angiotensin II receptor antagonist, TCV-116, and its metabolites in human serum and urine. J. Chromatogr., B 1996, 677, 123-132.
68. Timmermans, P. B. Pharmacological properties of angiotensin II receptor antagonists. Can. J. Cardiol. 1999, 15 (Suppl. F), 26F-28F.
69. Shibouta, Y.; Inada, Y.; Ojima, M.; Wada, T.; Noda, M.; et al. Angiotensin II-inhibitory action of candesartan cilexetil and its active metabolite, CV-11974, in rabbit aortic strips and conscious rats. Yakuri to Chiryo 1996, 24, 2207-2213.
70. Hanatani, T.; Fukuda, T.; Ikeda, M.; Imaoka, S.; Hiroi, T.; et al. CYP2C9*3 influences the metabolism and the drug-interaction of candesartan in vitro. Pharmacogenomics J. 2001, 1, 288-292.
71. Van Lier, J. J.; Van Heiningen, P. N. M.; Sunzel, M. Absorption, metabolism and excretion of 14C-candesartan and 14C-candesartan cilexetil in healthy volunteers. J. Hum. Hypertens. 1997, 11, S27-S28.
72. Fuchs, B.; Breithaupt-Grogler, K.; Belz, G. G.; Roll, S.; Malerczyk, C.; et al. Comparative pharmacodynamics and pharmacokinetics of candesartan and losartan in man. J. Pharm. Pharmacol. 2000, 52, 1075-1083.
73. Mallion, J. M.; Baguet, J. P. Putting the efficacy of candesartan cilexetil into perspective: a review of new comparative data. J. Hum. Hypertens. 2000, 14, S33-S41.
74. 14C]telmisartan in healthy volunteers. J. Clin. Pharmacol. 2000, 40, 1312-1322.
75. Ebner, T.; Heinzel, G.; Prox, A.; Beschke, K.; Wachsmuth, H. Disposition and chemical stability of telmisartan 1-O-acylglucuronide. Drug Metab. Dispos. 1999, 27, 1143-1149.
76. Mais, D. E.; Halushka, P. V.; Saussy, D. L. Eicosanoids in the cardiovascular and Renal Systems; MTP Press Limited: Lancaster, England, 1988; p 210.
77. Liu, E. C.; Hedberg, A.; Goldenberg, H. J.; Harris, D. N.; Webb, M. L. DuP 753, the selective angiotensin II receptor blocker, is a competitive antagonist to human platelet thromboxane A2/ prostaglandin H2 (TP) receptors. Prostaglandins 1992, 44, 89-99.
78. Perlman, S.; Schambye, H. T.; Rivero, R. A.; Greenlee, W. J.; Hjorth, S. A.; et al. Non-Peptide Angiotensin Agonist. J. Biol. Chem. 1994, 270, 1493-1496.
79. DeVita, R. J.; Bochis, R.; Frontier, A. J.; Kotliar, A.; Fisher, M. H.; et al. A Potent, Orally Bioavailable Benzazepinone Growth Hormone Secretagogue. J. Med. Chem. 1998, 41, 1716-1728.
80. Schoen, W. R.; Pisano, J. M.; Prendergast, K.; Matthew, J. Wyvratt, J.; Fisher, M. H.; et al. A Novel 3-Substituted Benzazepinone Growth Hormone Secretagogue (L-692,429). J. Med. Chem. 1994, 37, 897-906.
81. Smith, R. G.; Cheng, K.; Schoen, W. R.; Pong, S.-S.; Hickey, G.; et al. A Novel 3-Substituted Benzazepinone Growth Hormone Secretagogue (L-692,429). J. Med. Chem. 1993, 260, 1640-1643.
82. Nargund, R. P.; Patchett, A. A.; Bach, M. A.; Murphy, M. G.; Smith, R. G. Peptidomimetic Growth Hormone Secretagogues. Design Considerations and Therapeutic Potential. J. Med. Chem. 1998, 41, 3103-3127.
83. 2+ release channels (ryanodine receptors) and enhances cardiac function in cardiomyopathic hamsters. Cardiovasc. Res. 1998, 40, 64-73.
84. Sharma, R. K.; Smith, J. R.; Moore, G. J. Inhibition of Bovine Brain Calmodulin-Dependent cGMP Phosphodiesterase by Peptide and Non-Peptide Angiotensin Receptor Ligands. Biochem. Biophys. Res. Commun. 1991, 179, 85.
85. Segarra, V.; Crespo, I.; Pujol, F.; Beleta, J.; Doménech, T.; et al. Phosphodiesterase Inhibitory Properties of Losartan. Design and Synthesis of New Lead Compounds. Bioorg. Med. Chem. Lett. 1998, 8, 505-510.
86. Salmon, A. G. In Vitro Studies on Metabolism. Xenobiotic Metabolism and Disposition: The Design of Studies on Novel Compounds; CRC Press: Boca Raton, FL, 1989; pp 171-191.
87. Kramer, C.; Sunkomat, J.; Witte, J.; Luchtefeld, M.; Walden, M.; et al. Angiotensin II Receptor-Independent Antiinflammatory and Antiaggregatory Properties of Losartan: Role of the Active Metabolite EXP3179. Circ. Res. 2002, 90, 770-776.
88. Gonzalez, L.; Lopez, J. A.; Alonso, R. M.; Jimenez, R. M. Fast screening method for the determination of angiotensin II receptor antagonists in human plasma by high-performance liquid chromatography with fluorimetric detection. J. Chromatogr., A 2002, 949, 49-60.
89. Gonzalez, L.; Akesolo, U.; Jimenez, R. M.; Alonso, R. M. Application of capillary zone electrophoresis to the screening of some angiotensin II receptor antagonists. Electrophoresis 2002, 23, 223-229.
90. Gonzalez, L.; Alonso, R. M.; Jimenez, R. M. A high-performance liquid chromatographic method for screening angiotensin II receptor antagonists in human urine. Chromatographia 2000, 52, 735-740.
91. Palczewski, K.; Kumasaka, T.; Hori, T.; Behnke, C. A.; Motoshima, H.; et al. Crystal Structure of Rhodopsin: A G Protein-Coupled Receptor. Science 2000, 289, 739-745.
92. a determination of angiotensin II receptor antagonists (ARA II) by spectrofluorimetry. J. Pharm. Biomed. Anal. 2001, 26, 477-486.
93. Ishizaki, H.; Ohtawa, M. Inhibitory effect of the nonpeptide angiotensin II receptor antagonist losartan and its active metabolite, E-3174, on cAMP phosphodiesterase: additional action of the antagonists. Biochem. Pharmacol. 1994, 48, 201-204.
94. Ullrich, K. J.; Rumrich, G. Luminal transport step of paraaminohippurate (PAH): transport from PAH-loaded proximal tubular cells into the tubular lumen of the rat kidney. Pfluegers Arch. 1997, 433, 735-743.
95. Carini, D. J.; Duncia, J. V.; Aldrich, P. E.; Chiu, A. T.; Johnson, A. L.; et al. Nonpeptide Angiotensin II Receptor Antagonists: The Discovery of a Series of N-(Biphenylmethyl)imidazoles as Potent, Orally Active Antihypertensives. J. Med. Chem. 1991, 34, 2525-2547.
96. Martin, D. E.; Chapelsky, M. C.; Ilson, B.; Tenero, D.; Boike, S. C.; et al. Pharmacokinetics and Protein Binding of Eprosartan in Healthy Volunteers and in Patients with Varying Degrees of Renal Impairment. J. Clin. Pharmacol. 1998, 38, 129-137.
97. Mitscher, L. A.; Lednicer, D. The Organic Chemistry of Drug Synthesis; Wiley & Sons: New York, 1980; pp 301, 345.
98. Chang, S. Y.; Whigan, D. B.; Vachharajani, N. N.; Patel, R. Highperformance liquid chromatographic assay for the quantitation of irbesartan (SR 47436/BMS-186295) in human plasma and urine. J. Chromatogr., B 1997, 702, 149-155.
99. Marino, M. R.; Langenbacher, K.; Ford, N. F.; Uderman, H. D. Pharmacokinetics and pharmacodynamics of irbesartan in healthy subjects. J. Clin. Pharmacol. 1998, 38, 246-255.
100. Ruilope, L. Human pharmacokinetic/pharmacodynamic profile of irbesartan: a new potent angiotensin II receptor antagonist. J. Hypertens. 1997, 15 (Suppl.), 15-20.
101. Flesch, G.; Müller, P.; Lloyd, P. Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man. Eur. J. Clin. Pharmacol. 1997, 52, 115-120.
102. Müller, P.; Flesch, G.; de Gasparo, M.; Gasparini, M.; Howald, H. Pharmocokinetics and pharmacodynamic effects of the angiotensin II antagonist valsartan at steady state in healthy, normotensive rats. Eur. J. Clin. Pharmacol. 1997, 52, 441-449.
103. Brunner, H. R. The New Angiotensin II Receptor Antagonist, Irbesartan: Pharmacokinetic and Pharmacodynamic Considerations. Am. J. Hypertens. 1997, 10, 311-317.